Dawn Maier MSc, is the Sr. Director of Process Development and Manufacturing at ElevateBio and will be responsible for leading the process development and manufacturing teams. Dawn has over 17 years of research and GMP experience in multiple scientific disciplines. After receiving her Master of Biology degree from Western Carolina University, she began her career in 2002 at Thomas Jefferson University studying HIV and utilizing the SV40 virus for gene delivery. In 2007 she began working at UPENN’s Clinical Cell and Vaccine Production Facility (CVPF), where she focused on the translation and development of multiple novel manufacturing platforms in support of > 15 diverse early Phase I/II programs including various CAR T and TCR programs. In 2013, she joined bluebird bio and was responsible for building out in house process development capabilities as well as leading the teams in the development and tech transfer of the bb2121 CAR T product for Multiple Myeloma as well as Lenti-D and Lenti-G products for ALD, Beta Thal and Sickle cell disease. In 2017 she went on to lead the process and analytical development teams at Unum Therapeutics, for their Antibody Coupled T cell Receptor (ACTR) platform and using gamma retroviruses for transgene delivery.